Pharmaceutical Packaging Market (2026-2036)

The growth of this market is mainly driven by glucagon-like peptide-1 and biologic injectable volumes that now account for roughly a fifth of revenue at the leading drug containment suppliers, the shift from bulk components to ready-to-use sterile formats, drug delivery devices and combination products growing faster than the containers they attach to, sterile manufacturing capacity investment at unprecedented scale, and serialisation and traceability requirements that attach value to secondary packaging. However, standard and commodity component lines growing at under one percent, contraction in moulded glass and oral liquid containment, European packaging regulation that adds compliance cost without adding value, and ramp-up costs at new capacity that are diluting supplier margins restrain the growth of this market.

Beyond these, ready-to-use vials, syringes and cartridges, autoinjector and pen platforms, cold chain and cryogenic packaging for cell and gene therapies, and contract filling capacity are expected to create significant growth opportunities for the stakeholders in this market.

The Pharmaceutical Packaging Market comprises the materials, containers, closures, devices and packs that contain, protect, deliver and identify medicinal products. Consistent with the scope of the preceding edition, the market covers polymer materials including polyvinyl chloride, polyethylene terephthalate, polypropylene, polyethylene and cyclic olefin polymer, together with glass, paper and paperboard, metal and other materials including rubber and silica gel; primary packaging spanning blister packaging, bottles, vials and ampoules, caps and closures, pre-fillable inhalers, pre-fillable syringes and cartridges and pouches and sachets, alongside secondary and tertiary packaging; oral solid, oral liquid, parenteral and other dosage forms; and pharmaceutical companies, contract companies and pharmacies as end users. This edition adds drug type, product format, functionality and temperature requirement.

The ecosystem spans resin, borosilicate tubing, elastomer compound and aluminium suppliers; converters producing tubing, moulded and formed containers; closure, stopper and seal manufacturers; device developers supplying autoinjectors, pens and inhalers; printers and label converters; serialisation and coding providers; washing, depyrogenation and sterilisation service providers; contract development and manufacturing organisations performing fill-finish and assembly; and the pharmaceutical, biotechnology and generic manufacturers and pharmacies that use the resulting packs.

Several adjacent categories remain outside this market. Filling, inspection, labelling and cartoning machinery is counted as capital equipment rather than as packaging, as are laboratory consumables, surgical and wound care packaging, nutraceutical packaging, and the active pharmaceutical ingredient itself. Cold chain logistics services are excluded while the passive and active packaging systems that maintain temperature are included.

The defining finding of this edition is that this market has divided between high-value drug delivery and containment components and the standard lines that carry most of the volume. West Pharmaceutical Services reported second-quarter 2026 net sales of USD 872.3 million, up 13.8% and 12.7% organic, with gross margin rising to 37.7% and adjusted diluted earnings per share up 28.8% to USD 2.37. Within Proprietary Products revenue of USD 722.6 million, up 16.6%, High-Value Product Components rose 19.4% to USD 424.1 million and High-Value Product Delivery Devices rose 29.6% to USD 131.2 million, while Standard Products rose only 0.7% organic to USD 167.3 million and the West Vantage contract segment rose 0.8% organic.

The same division appears by therapeutic area rather than by product line. West Pharmaceutical reported biologics sales of USD 374.8 million, up 30.3% and 29.2% organic, against generics at USD 142.8 million, up 6.9%, and attributed High-Value Product Component growth to ongoing growth in glucagon-like peptide-1 elastomers. Full-year 2026 guidance was raised to net sales of USD 3.345 billion to USD 3.380 billion, implying organic growth of 10.0% to 11.0%, and adjusted diluted earnings per share of USD 8.85 to USD 9.05 from a prior USD 8.40 to USD 8.75, with capital spending unchanged at USD 250 million to USD 275 million.

Stevanato Group quantifies the metabolic injectable contribution directly. Second-quarter 2026 revenue reached EUR 302 million, up 8%, with Biopharmaceutical and Diagnostic Solutions at EUR 266 million, up 9% and 10% at constant currency, and Engineering at EUR 36 million, down 2%. High-value solutions revenue of EUR 136 million rose 16% and 18% at constant currency, representing approximately 51% of segment revenue and 45% of total revenue, and the company stated that glucagon-like peptide-1 products accounted for approximately 22% to 23% of revenue. Adjusted EBITDA rose 21% to EUR 78.7 million at a 26.0% margin, and full-year guidance implies 8% to 10% organic growth.

Capacity decisions show where the market is moving faster than any forecast statement. Stevanato is ramping high-value prefilled syringe capacity at Latina, expects to install its first next-generation ready-to-use 400 EZ-fill cartridge line within months for commercial production in early 2027, completed performance qualification on its first EZ-fill vial line at Fishers with customer validations starting, and expects drug delivery system contract manufacturing to reach commercial production at the end of 2026. Those sites remain margin-dilutive while gaining operating leverage, with second-quarter capital expenditure of EUR 52.0 million and free cash flow of negative EUR 32.0 million.

Glass has divided within itself, which complicates any single reading of the material segmentation. SCHOTT Pharma reported third-quarter fiscal 2026 revenue of EUR 282 million, up 10% and 8.3% at constant currency, and raised full-year guidance to 5% to 6% constant-currency growth from 2% to 5% with the adjusted EBITDA margin to 27% to 28%. Drug Containment Solutions revenue rose 10.8% organically to EUR 159 million at a 23.8% segment margin, while Drug Delivery Systems revenue rose 5.4% organically to EUR 123 million with its margin falling to 29.4% from 36.9% on lower polymer syringe capacity utilisation. The company described a recovery in polymer syringes alongside sustained demand for glucagon-like peptide-1 glass syringes.

Gerresheimer provides the counterweight, and it is substantial. The company cut 2025 guidance on 8 October 2025 to an organic revenue decline of 4% to 2% against prior growth of 0% to 2%, and the adjusted EBITDA margin to approximately 18.5% to 19% from approximately 20%, citing slower market growth and subdued demand in cosmetics and oral liquids. Nine-month 2025 revenue of EUR 1,681.4 million rose 14.6% as reported but fell 1.8% organically, adjusted EBITDA fell 7.5% organically, Primary Packaging Glass revenue of EUR 714.4 million fell 6.9% organically, and Plastics and Devices revenue of EUR 972.6 million grew only 2.6% organically with its margin falling to 22.9% from 25.2%.

Within that decline the composition is instructive. Gerresheimer attributed the glass weakness primarily to moulded glass and to plastic containment for oral liquids, while reporting that demand for its ready-to-fill vials was positive and that strong drug delivery demand offset the weakness. The Moulded Glass business was separated into its own division from 2026 with a sale process prepared for that year, and the company subsequently cut its 2026 outlook citing project delays and production expansion costs, reported lower half-year core profit and halted discussions on a potential takeover. Injectable glass and drug delivery therefore grew while commodity glass and oral liquid containment contracted inside the same company.

Sterile capacity investment supports parenteral packaging demand across the forecast period. Eli Lilly announced in February 2025 that it expects more than USD 50 billion of United States capital expenditure including commitments made since 2020, comprising USD 27 billion of new investment across four facilities of which one supports its global network for injectable therapies, against annual capital expenditure of approximately USD 1.4 billion before 2022, USD 3.45 billion in 2023 and USD 5.06 billion in 2024. Novo Nordisk committed approximately USD 4.1 billion to a fill-finish facility at Clayton, North Carolina, completing between 2027 and 2029.

European good manufacturing practice sets the quality requirements those packs must meet. Annex 1 on the manufacture of sterile products requires at paragraph 8.21 that containers closed by fusion, including blow-fill-seal, form-fill-seal, parenteral bags and ampoules, be subject to 100% integrity testing and states that visual inspection alone is not an acceptable integrity test method, while paragraph 8.29 requires filled parenteral containers to be inspected individually with a maintained defect library. Paragraph 8.31 requires automated inspection to be validated as equal to or better than manual methods, and paragraph 8.32 requires defect types and reject levels to be trended statistically.

European packaging law now applies, and its treatment of pharmaceutical formats is more specific than general commentary suggests. Regulation (EU) 2025/40 on packaging and packaging waste applies from 12 August 2026, and Commission Notice C/2026/3084, a guidance document published in the Official Journal C series on 10 June 2026 covering thirty-three topics including per- and polyfluoroalkyl substance limits, recyclability, recycled content and minimisation, confirms two points of direct consequence. Intravenous bags and syringes are not packaging even when sold pre-filled, because they are integral delivery devices. Harmonised sorting-label requirements do not apply to packaging for medicinal products, medical devices and in vitro diagnostics usable only by professional end users.

The commercial effect of that drafting is to concentrate compliance cost where value is lowest. Recyclability, recycled content, minimisation and substance restrictions fall on secondary cartons, leaflets, labels and tertiary transport packaging, while the highest-value primary formats, prefilled syringes above all, fall outside the definition of packaging altogether. Serialisation requirements reinforce the same point, because the unique identifier, aggregation data and tamper evidence live on the secondary carton rather than on the container, which is why this edition treats secondary packaging as the faster-growing packaging type despite primary packaging remaining much the larger.

Over the forecast period, market value is expected to grow from USD 119.80 billion in 2026 to USD 236.50 billion in 2036. Growth is led by glucagon-like peptide-1 and biologic injectable volumes, the shift to ready-to-use sterile formats, drug delivery devices, sterile capacity investment and serialisation requirements. It is moderated by standard component lines growing at under one percent, contraction in moulded glass and oral liquid containment, European packaging compliance cost that adds no value, and ramp-up costs diluting supplier margins. The resulting CAGR of 7.0% reflects a market whose high-value minority compounds at 16% to 30% while its commodity majority grows at low single digits.

Base Year

2025

Historical Years

2023-2024

Forecast Period

2026-2036

Market Size in 2025

USD 112.40 Billion

Market Size in 2026

USD 119.80 Billion

Market Size in 2036

USD 236.50 Billion

CAGR (2026-2036)

7.0%

Largest Material in 2026

Polymer

Fastest-Growing Material

Glass

Largest Packaging Type in 2026

Primary Packaging

Fastest-Growing Packaging Type

Secondary Packaging

Largest Dosage Form in 2026

Oral Solid Formulations

Fastest-Growing Dosage Form